TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 33389390

Group type: EXPERIMENTAL
Intervention: Emotion coaching parenting intervention (Tuning in to Kids® program), 6 weekly sessions
Number of subjects: 89

Group type: COMPARATOR
Intervention: Waitlist control group
Number of subjects: 89
Study: 34627259

Group type: EXPERIMENTAL
Intervention: Care pathways for symptom management
Number of subjects: 23

Group type: EXPERIMENTAL
Intervention: COVID-19 pandemic impact
Number of subjects: 23
Study: 32753268

Group type: EXPERIMENTAL
Intervention: Edoxaban 60 mg
Number of subjects: 2199

Group type: COMPARATOR
Intervention: Enoxaparin–warfarin
Number of subjects: 2199
Study: 34704543

Group type: EXPERIMENTAL
Intervention: Moderate intensity aerobic cycling
Number of subjects: 5

Group type: COMPARATOR
Intervention: Active control
Number of subjects: 5
Study: 33447376

Group type: EXPERIMENTAL
Intervention: Dexamethasone
Number of subjects: 2000

Group type: EXPERIMENTAL
Intervention: Hydroxychloroquine
Number of subjects: 2000

Group type: EXPERIMENTAL
Intervention: Rapid recruitment and dissemination
Number of subjects: 2000

Group type: EXPERIMENTAL
Intervention: Hypothetical increased recruitment to 50%
Number of subjects: 2000
Study: 34329897

Group type: EXPERIMENTAL
Intervention: Gabapentin enacarbil (GE) 600 mg
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Gabapentin enacarbil (GE)
Number of subjects: 0
Study: 36344973

Group type: EXPERIMENTAL
Intervention: Low-intensity health education (LIHE)
Number of subjects: 756

Group type: EXPERIMENTAL
Intervention: High-intensity health education (HIHE)
Number of subjects: 756

Group type: EXPERIMENTAL
Intervention: Medium-intensity health education (MIHE)
Number of subjects: 756

Group type: COMPARATOR
Intervention: Control group (CG)
Number of subjects: 756
Study: 32694214

Group type: EXPERIMENTAL
Intervention: Dapagliflozin/Saxagliptin (DAPA/SAXA) 10/5 mg
Number of subjects: 56

Group type: EXPERIMENTAL
Intervention: Dapagliflozin (DAPA) 10 mg
Number of subjects: 56

Group type: COMPARATOR
Intervention: Placebo (PCB)
Number of subjects: 56
Study: 34863853

Group type: EXPERIMENTAL
Intervention: ritlecitinib
Number of subjects: 46

Group type: EXPERIMENTAL
Intervention: brepocitinib
Number of subjects: 46

Group type: COMPARATOR
Intervention: placebo
Number of subjects: 46
Study: 34776200

Group type: EXPERIMENTAL
Intervention: Core stability training program (3 times a week for 8 weeks)
Number of subjects: 20
Study: 32043211

Group type: EXPERIMENTAL
Intervention: UTP (P2Y2R stimulator, 100 μM) and CPA (cryoprotectants)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Suramin (P2Y2R inhibitor, 100 μM)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: CPA and UTP
Number of subjects: 0
Study: 34696892

Group type: EXPERIMENTAL
Intervention: Regorafenib at 160 or 120 mg daily, 3 weeks on/1 week off
Number of subjects: 116

Group type: COMPARATOR
Intervention: Tamoxifen at 40 mg daily
Number of subjects: 116

Group type: EXPERIMENTAL
Intervention: Regorafenib
Number of subjects: 116

Group type: COMPARATOR
Intervention: Tamoxifen
Number of subjects: 116
Study: 33827639

Group type: EXPERIMENTAL
Intervention: Prebiotic (oligofructose‐enriched inulin; 16 g/day)
Number of subjects: 60

Group type: COMPARATOR
Intervention: Calorie‐matched placebo (maltodextrin)
Number of subjects: 60
Study: 33972312

Group type: EXPERIMENTAL
Intervention: MethSig (DNAme driver inference framework)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: CRISPR/Cas9 knockout of selected candidate CLL DNAme drivers
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: DNAme driver risk score
Number of subjects: 0
Study: 32294559

Group type: EXPERIMENTAL
Intervention: aPDT with Bixa orellana extract (20% w/v) and blue LED (395-480 nm)
Number of subjects: 44

Group type: COMPARATOR
Intervention: Tongue scraping
Number of subjects: 44

Group type: EXPERIMENTAL
Intervention: Tongue scraping and aPDT
Number of subjects: 44
Study: 33960497

Group type: EXPERIMENTAL
Intervention: Observation group (n=19)
Number of subjects: 59

Group type: COMPARATOR
Intervention: Completion lymph node dissection group (n=40)
Number of subjects: 59
Study: 35672195

Group type: EXPERIMENTAL
Intervention: Contralateral submental artery island flap (CSIF)
Number of subjects: 64

Group type: COMPARATOR
Intervention: Primary closure (PC)
Number of subjects: 64
Study: 33985385

Group type: EXPERIMENTAL
Intervention: -40 mmHg INP treatment for 1 hour twice daily for 12 weeks
Number of subjects: 61

Group type: COMPARATOR
Intervention: -10 mmHg INP sham control treatment for 1 hour twice daily for 12 weeks
Number of subjects: 61
Study: 33456773

Group type: EXPERIMENTAL
Intervention: PRECLUDE®MVP alone
Number of subjects: 35

Group type: EXPERIMENTAL
Intervention: PRECLUDE®MVP with autogenous bone graft or titanium mesh
Number of subjects: 35
Study: 33118102

Group type: EXPERIMENTAL
Intervention: ICSI (Intracytoplasmic Sperm Injection)
Number of subjects: 60

Group type: COMPARATOR
Intervention: Conventional IVF (In Vitro Fertilization)
Number of subjects: 60
Study: 35210509

Group type: EXPERIMENTAL
Intervention: Comprehensive geriatric assessment (CGA)
Number of subjects: 86
Study: 33661996

Group type: EXPERIMENTAL
Intervention: Abstinence‐Related Motivational Engagement (ARME) scale
Number of subjects: 1874

Group type: EXPERIMENTAL
Intervention: Situation‐specific Abstinence Self‐Efficacy (SSE) scale
Number of subjects: 1874

Group type: COMPARATOR
Intervention: ARME and SSE measures
Number of subjects: 1874
Study: 35139487

Group type: EXPERIMENTAL
Intervention: Da‐Cheng‐Qi Decoction (DCQD)
Number of subjects: 114

Group type: COMPARATOR
Intervention: Conventional medical treatment
Number of subjects: 114
Study: 33840592

Group type: EXPERIMENTAL
Intervention: KFAC and PC with wide phase duration (500 µs)
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: KFAC and PC with narrow phase duration (200 µs)
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: KFAC and PC with phase duration (500 µs)
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: KFAC and PC with phase duration (200 µs)
Number of subjects: 24
Study: 36098062

Group type: EXPERIMENTAL
Intervention: Crystalloids
Number of subjects: 80

Group type: COMPARATOR
Intervention: Colloids
Number of subjects: 80
Study: 34071560

Group type: EXPERIMENTAL
Intervention: TEENS+ intervention (individualized dietary goals of 1200-1800 kcal/day)
Number of subjects: 82

Group type: EXPERIMENTAL
Intervention: TEENS+ intervention
Number of subjects: 82
Study: 33210555

Group type: EXPERIMENTAL
Intervention: Half-padded cycling pad
Number of subjects: 183

Group type: COMPARATOR
Intervention: Full-padded cycling bib shorts
Number of subjects: 183
Study: 36484214

Group type: EXPERIMENTAL
Intervention: Absorb bioresorbable scaffold (BRS)
Number of subjects: 120

Group type: COMPARATOR
Intervention: Xience drug-eluting stent (DES)
Number of subjects: 120

Group type: EXPERIMENTAL
Intervention: Both groups (BRS and DES)
Number of subjects: 120
Study: 33756301

Group type: EXPERIMENTAL
Intervention: Cigalike (18 mg/mL)
Number of subjects: 50

Group type: EXPERIMENTAL
Intervention: Tank (18 mg/mL)
Number of subjects: 50

Group type: EXPERIMENTAL
Intervention: Tank (6 mg/mL)
Number of subjects: 50
Study: 33196747

Group type: EXPERIMENTAL
Intervention: Tazarotene 0.045% lotion
Number of subjects: 1614

Group type: COMPARATOR
Intervention: Vehicle lotion
Number of subjects: 1614
Study: 34622734

Group type: EXPERIMENTAL
Intervention: CET + acamprosate
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: CET monotherapy
Number of subjects: 0

Group type: COMPARATOR
Intervention: AAU monotherapy
Number of subjects: 0

Group type: COMPARATOR
Intervention: AAU + acamprosate
Number of subjects: 0
Study: 33242736

Group type: EXPERIMENTAL
Intervention: Early feeding (starting fluids and soft diet on the day following surgery)
Number of subjects: 200

Group type: COMPARATOR
Intervention: Late feeding (five-day post-operative period of 'nil by mouth')
Number of subjects: 200

Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 200
Study: 32804950

Group type: EXPERIMENTAL
Intervention: Vi vaccine
Number of subjects: 70566

Group type: COMPARATOR
Intervention: Control (Hepatitis A vaccine)
Number of subjects: 70566
Study: 35386039

Group type: EXPERIMENTAL
Intervention: Women United: Clinical Trials and the Fight Against Breast Cancer Program (intervention group, n=215)
Number of subjects: 422

Group type: COMPARATOR
Intervention: Control program (control group, n=207)
Number of subjects: 422
Study: 33844409

Group type: EXPERIMENTAL
Intervention: ROLLIS
Number of subjects: 123

Group type: COMPARATOR
Intervention: HWL
Number of subjects: 123
Study: 35820713

Group type: EXPERIMENTAL
Intervention: Novel algorithm and software for early detection of acute illness
Number of subjects: 273
Study: 34622764

Group type: EXPERIMENTAL
Intervention: Apremilast 30 mg twice daily for 12 weeks, followed by continued treatment through Week 64
Number of subjects: 207

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 207
Study: 32414338

Group type: EXPERIMENTAL
Intervention: Management algorithm including extended focused assessment of sonography for HIV and tuberculosis (eFASH) in combination with chest X-ray and microbiological tests.
Number of subjects: 650

Group type: COMPARATOR
Intervention: National guidelines management (control group).
Number of subjects: 650
Study: 35393384

Group type: EXPERIMENTAL
Intervention: N-acetylcysteine (NAC) plus standard care
Number of subjects: 65

Group type: COMPARATOR
Intervention: Standard care alone
Number of subjects: 65
Study: 34062535

Group type: EXPERIMENTAL
Intervention: HBM-based intervention
Number of subjects: 136

Group type: COMPARATOR
Intervention: Control group (PR program only)
Number of subjects: 136
Study: 33003389

Group type: EXPERIMENTAL
Intervention: Enriched protein drink (protein+)
Number of subjects: 123

Group type: COMPARATOR
Intervention: Isocaloric control drink (control)
Number of subjects: 123

Group type: EXPERIMENTAL
Intervention: Lifestyle intervention (both groups)
Number of subjects: 123

Group type: EXPERIMENTAL
Intervention: Lifestyle intervention (MIR subgroup)
Number of subjects: 123

Group type: EXPERIMENTAL
Intervention: Lifestyle intervention (no-MIR subgroup)
Number of subjects: 123
Study: 34974413

Group type: EXPERIMENTAL
Intervention: Azithromycin (250 mg OD)
Number of subjects: 77

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 77
Study: 33539318

Group type: EXPERIMENTAL
Intervention: Tripterygium glycosides (TG) 20 mg tablet three times per day for 24 weeks
Number of subjects: 161

Group type: COMPARATOR
Intervention: Intravenous methylprednisolone (iv.MP) 500 mg once per week for 6 weeks followed by 250 mg per week for 6 weeks
Number of subjects: 161

Group type: EXPERIMENTAL
Intervention: Tripterygium glycosides (TG)
Number of subjects: 161

Group type: COMPARATOR
Intervention: Intravenous methylprednisolone (iv.MP)
Number of subjects: 161
Study: 33235030

Group type: EXPERIMENTAL
Intervention: Dapansutrile 2000 mg
Number of subjects: 30

Group type: COMPARATOR
Intervention: Dapansutrile (all cohorts)
Number of subjects: 30
Study: 35775120

Group type: EXPERIMENTAL
Intervention: Buddy-style intervention (5-10 min once a week for 12 weeks)
Number of subjects: 65

Group type: COMPARATOR
Intervention: Control group (12-week home-based exercise program without buddy-style intervention)
Number of subjects: 65

Group type: EXPERIMENTAL
Intervention: Buddy-style intervention
Number of subjects: 65

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 65
Study: 34574458

Group type: EXPERIMENTAL
Intervention: Chinese herbal medicine (CHM) - Angelicae Sinensis Radix
Number of subjects: 48

Group type: EXPERIMENTAL
Intervention: Chinese herbal medicine (CHM) - Astragali Radix
Number of subjects: 48

Group type: EXPERIMENTAL
Intervention: Chinese herbal medicine (CHM) - Salviae Miltiorrhizae Radix et Rhizoma
Number of subjects: 48

Group type: COMPARATOR
Intervention: Control group (other CHM products)
Number of subjects: 48
Study: 32815840

Group type: EXPERIMENTAL
Intervention: Volar plate with addition of a dorsal ulnar pin plate
Number of subjects: 18

Group type: COMPARATOR
Intervention: Volar plate only
Number of subjects: 18
Study: 34320853

Group type: EXPERIMENTAL
Intervention: Culturally tailored parent education program
Number of subjects: 109

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 109
Study: 34656033

Group type: EXPERIMENTAL
Intervention: Low-carbohydrate (LC) diet
Number of subjects: 48

Group type: COMPARATOR
Intervention: Calorie-restricted (CR) diet
Number of subjects: 48
Study: 35549984

Group type: EXPERIMENTAL
Intervention: Early parenteral nutrition (early-PN)
Number of subjects: 521

Group type: COMPARATOR
Intervention: Late parenteral nutrition (late-PN)
Number of subjects: 521
Study: 32429737

Group type: EXPERIMENTAL
Intervention: Tart Cherry Juice (240 mL, twice daily for 12 weeks)
Number of subjects: 19

Group type: COMPARATOR
Intervention: Control (isocaloric placebo drink, twice daily for 12 weeks)
Number of subjects: 19
Study: 36575506

Group type: EXPERIMENTAL
Intervention: 200 mL of a clear supplement containing 10 g of whey protein and 54 g of carbohydrates (WP+CHO)
Number of subjects: 0

Group type: COMPARATOR
Intervention: 200 mL of a clear supplement containing 12.5% maltodextrin (25 g) (CHO)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Fasting period of 8 hours
Number of subjects: 0
Study: 33647827

Group type: EXPERIMENTAL
Intervention: Blended cognitive dissonance
Number of subjects: 98

Group type: EXPERIMENTAL
Intervention: Standard cognitive dissonance
Number of subjects: 98

Group type: COMPARATOR
Intervention: Blended control
Number of subjects: 98

Group type: COMPARATOR
Intervention: Standard control
Number of subjects: 98

Group type: EXPERIMENTAL
Intervention: Blended cognitive dissonance (with higher in-group identification)
Number of subjects: 98
Study: 36064604

Group type: EXPERIMENTAL
Intervention: Topical application of ABCB5+ mesenchymal stem cells (MSCs)
Number of subjects: 23
Study: 34128498

Group type: EXPERIMENTAL
Intervention: Operative treatment (plate fixation with a precontoured distal clavicular plate or a 'hook' plate within 28 days from injury)
Number of subjects: 57

Group type: COMPARATOR
Intervention: Nonoperative treatment (standard shoulder sling, followed by pendulum or gentle range of motion shoulder exercises)
Number of subjects: 57

Group type: EXPERIMENTAL
Intervention: Operative treatment
Number of subjects: 57

Group type: COMPARATOR
Intervention: Nonoperative treatment
Number of subjects: 57
Study: 32920032

Group type: EXPERIMENTAL
Intervention: 2% lidocaine gel
Number of subjects: 120

Group type: COMPARATOR
Intervention: water soluble gel
Number of subjects: 120

Group type: EXPERIMENTAL
Intervention: flexible cystoscopy
Number of subjects: 120

Group type: COMPARATOR
Intervention: rigid cystoscopy
Number of subjects: 120
Study: 35768085

Group type: EXPERIMENTAL
Intervention: Gain framing education videos about self-management skills for type 2 diabetes
Number of subjects: 84

Group type: EXPERIMENTAL
Intervention: Loss framing education videos about self-management skills for type 2 diabetes
Number of subjects: 84

Group type: COMPARATOR
Intervention: Education with no specific message framing
Number of subjects: 84

Group type: EXPERIMENTAL
Intervention: Gain framing education videos
Number of subjects: 84

Group type: EXPERIMENTAL
Intervention: Loss framing education videos
Number of subjects: 84
Study: 34195206

Group type: EXPERIMENTAL
Intervention: Short-term low-dose lithium therapy for three consecutive days
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo treatment for three consecutive days
Number of subjects: 0
Study: 34649083

Group type: EXPERIMENTAL
Intervention: Electronic clinical pathway (CPW)
Number of subjects: 156

Group type: COMPARATOR
Intervention: Control 'treatment as usual' (TAU)
Number of subjects: 156
Study: 35790596

Group type: EXPERIMENTAL
Intervention: CUES© intervention, 72% attendance at 4–8 sessions
Number of subjects: 50

Group type: COMPARATOR
Intervention: Enhanced services as usual
Number of subjects: 50
Study: 34473448

Group type: EXPERIMENTAL
Intervention: WhatsApp text messaging and motivational individual counseling, sent 3 days a week.
Number of subjects: 50

Group type: COMPARATOR
Intervention: Control group (no WhatsApp text messaging or counseling).
Number of subjects: 50

Group type: EXPERIMENTAL
Intervention: WhatsApp text messaging and motivational individual counseling.
Number of subjects: 50
Study: 32603494

Group type: EXPERIMENTAL
Intervention: Somapacitan
Number of subjects: 62

Group type: COMPARATOR
Intervention: Daily GH
Number of subjects: 62
Study: 35678020

Group type: EXPERIMENTAL
Intervention: Argatroban plus dual antiplatelet therapy (DAPT)
Number of subjects: 120

Group type: COMPARATOR
Intervention: DAPT only (control group)
Number of subjects: 120
Study: 33337738

Group type: EXPERIMENTAL
Intervention: Gadoterate administration after premedication with corticosteroid and diphenhydramine
Number of subjects: 26

Group type: EXPERIMENTAL
Intervention: Gadoterate administration with corticosteroid premedication
Number of subjects: 26

Group type: EXPERIMENTAL
Intervention: Gadoterate administration without corticosteroid premedication
Number of subjects: 26
Study: 32925623

Group type: EXPERIMENTAL
Intervention: 1 mg oral E2 with or without vaginal progesterone
Number of subjects: 275
Study: 35177066

Group type: EXPERIMENTAL
Intervention: Cholecalciferol (100,000 IU)
Number of subjects: 543

Group type: COMPARATOR
Intervention: Control (nothing)
Number of subjects: 543
Study: 34358724

Group type: EXPERIMENTAL
Intervention: Sintilimab plus chemotherapy
Number of subjects: 397

Group type: COMPARATOR
Intervention: Placebo plus chemotherapy
Number of subjects: 397
Study: 32058077

Group type: EXPERIMENTAL
Intervention: Avatar-Simon task with rapidly changing avatar positions and simultaneous presentations
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Avatar-Simon task with rapidly changing avatar positions and non-simultaneous presentations
Number of subjects: 0
Study: 34098728

Group type: EXPERIMENTAL
Intervention: Extracorporeal physical vibrational lithecbole (EPVL) through greater sciatic foramen (GSF)
Number of subjects: 181

Group type: COMPARATOR
Intervention: Abdominal treatment
Number of subjects: 181

Group type: COMPARATOR
Intervention: Combined with oral use of tamsulosin at 0.4 mg daily
Number of subjects: 181
Study: 33091320

Group type: EXPERIMENTAL
Intervention: Community health worker home visits
Number of subjects: 1469

Group type: COMPARATOR
Intervention: Standard clinic care
Number of subjects: 1469
Study: 34875413

Group type: EXPERIMENTAL
Intervention: Previous infant with maternally reported respiratory morbidity
Number of subjects: 1412

Group type: COMPARATOR
Intervention: No previous infant with maternally reported respiratory morbidity
Number of subjects: 1412

Group type: EXPERIMENTAL
Intervention: No betamethasone use
Number of subjects: 1412

Group type: COMPARATOR
Intervention: Betamethasone use
Number of subjects: 1412
Study: 33683016

Group type: EXPERIMENTAL
Intervention: Drug being tested to prevent hypertensive complications
Number of subjects: 1

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 1
Study: 32819842

Group type: EXPERIMENTAL
Intervention: Follitropin delta 10.0 µg
Number of subjects: 1591

Group type: EXPERIMENTAL
Intervention: Follitropin delta 10.3 µg
Number of subjects: 1591

Group type: EXPERIMENTAL
Intervention: Follitropin delta 9.7 µg
Number of subjects: 1591

Group type: EXPERIMENTAL
Intervention: Follitropin delta 9.3 µg
Number of subjects: 1591

Group type: EXPERIMENTAL
Intervention: Follitropin delta 9.5–10.4 µg
Number of subjects: 1591

Group type: COMPARATOR
Intervention: 150 IU/day follitropin alfa
Number of subjects: 1591
Study: 34298007

Group type: EXPERIMENTAL
Intervention: e‐hookah vaping
Number of subjects: 17

Group type: COMPARATOR
Intervention: combustible hookah smoking
Number of subjects: 17
Study: 32897605

Group type: EXPERIMENTAL
Intervention: Transesophageal echocardiography (TEE)
Number of subjects: 34
Study: 35246827

Group type: EXPERIMENTAL
Intervention: fosnetupitant 235 mg
Number of subjects: 785

Group type: COMPARATOR
Intervention: fosaprepitant 150 mg
Number of subjects: 785
Study: 33871574

Group type: EXPERIMENTAL
Intervention: Diet rich in saturated fatty acids from cheese
Number of subjects: 92

Group type: EXPERIMENTAL
Intervention: Diet rich in saturated fatty acids from butter
Number of subjects: 92

Group type: EXPERIMENTAL
Intervention: Diet rich in monounsaturated fatty acids (MUFAs)
Number of subjects: 92

Group type: EXPERIMENTAL
Intervention: Diet rich in n‐6 polyunsaturated fatty acids (PUFAs)
Number of subjects: 92

Group type: EXPERIMENTAL
Intervention: Diet higher in carbohydrates (CHO)
Number of subjects: 92

Group type: COMPARATOR
Intervention: All diets
Number of subjects: 92
Study: 35866500

Group type: EXPERIMENTAL
Intervention: Tertile 3 (T3) average 1-year home blood pressure
Number of subjects: 242

Group type: EXPERIMENTAL
Intervention: Average 1-year home blood pressure
Number of subjects: 242
Study: 33674863

Group type: EXPERIMENTAL
Intervention: Disease self-management app delivering 1-2 tailored messages/day for 16 weeks
Number of subjects: 110
Study: 32740469

Group type: EXPERIMENTAL
Intervention: Dabigatran
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Warfarin
Number of subjects: 0
Study: 35220498

Group type: EXPERIMENTAL
Intervention: Supervised passive trunk stretching using the exercise ball (EB)
Number of subjects: 12

Group type: COMPARATOR
Intervention: Resting and sitting trial (CON)
Number of subjects: 12
Study: 32756282

Group type: EXPERIMENTAL
Intervention: High hand grip strength (HGS) group (n=26)
Number of subjects: 78

Group type: COMPARATOR
Intervention: Low hand grip strength (HGS) group (n=52)
Number of subjects: 78
Study: 36038180

Group type: EXPERIMENTAL
Intervention: Nutri-Score
Number of subjects: 1180

Group type: COMPARATOR
Intervention: Reference Intakes (RIs)
Number of subjects: 1180

Group type: COMPARATOR
Intervention: No label
Number of subjects: 1180

Group type: COMPARATOR
Intervention: RIs
Number of subjects: 1180
Study: 32062872

Group type: EXPERIMENTAL
Intervention: OIR trials (Other-Initiated Repairs)
Number of subjects: 88

Group type: COMPARATOR
Intervention: Trials without OIR
Number of subjects: 88

Group type: EXPERIMENTAL
Intervention: OIR trials
Number of subjects: 88

Group type: EXPERIMENTAL
Intervention: Repeated social interactions
Number of subjects: 88

Group type: EXPERIMENTAL
Intervention: Overall communication
Number of subjects: 88
Study: 33413569

Group type: EXPERIMENTAL
Intervention: Specific acupoints group
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Non-specific acupoints group
Number of subjects: 60

Group type: COMPARATOR
Intervention: Non-acupoints group
Number of subjects: 60
Study: 36127077

Group type: EXPERIMENTAL
Intervention: Early ICU-VR group (ICU-VR within 2 weeks after ICU discharge)
Number of subjects: 300

Group type: EXPERIMENTAL
Intervention: Late ICU-VR group (ICU-VR during the post-ICU follow-up visit)
Number of subjects: 300

Group type: COMPARATOR
Intervention: Usual care group (including a mandatory ICU follow-up clinic visit 3 months after ICU discharge)
Number of subjects: 300

Group type: EXPERIMENTAL
Intervention: All groups (early ICU-VR, late ICU-VR, and usual care)
Number of subjects: 300
Study: 34020596

Group type: EXPERIMENTAL
Intervention: Goal-Directed Fluid Therapy (GDFT)
Number of subjects: 120

Group type: COMPARATOR
Intervention: Conventional Fluid Therapy (CFT)
Number of subjects: 120